Prognostic and clinicopathological value of FoxM1 expression in colorectal cancer: A systematic review and meta-analysis
- PMID: 30593202
- PMCID: PMC6314739
- DOI: 10.1097/MD.0000000000013899
Prognostic and clinicopathological value of FoxM1 expression in colorectal cancer: A systematic review and meta-analysis
Abstract
Background: The study aims to assess the relationship between FoxM1 expression and clinicopathological parameters and prognosis of patients diagnosed with colorectal cancer (CRC) by summarizing the studies included.
Methods: PubMed, EMBASE, The Cochrane Library and other sources were searched for relative studies. Odds ratio (OR) and confidence interval (CI) were used to assess association between FoxM1 expression and clinical parameters and prognosis of CRC patients.
Results: Eight studies were included in the final analysis, with 1149 CRC patients. The outcome revealed that expression of FoxM1 was associated with lymph node metastasis (OR = 0.33, 95%CI = 0.19-0.62, P < .001), distant metastasis (OR = 0.35, 95%CI = 0.24-0.46, P < .001) and tumor node metastasis (TNM) stage (OR = 0.45, 95%CI = 0.29-0.72, P < .001). Meanwhile, reduced FoxM1 expression indicated higher 5-year survival rate (OR = 0.38, 95%CI = 0.18-0.78, P = .01). Expression of FoxM1 was also increased obviously in CRC tissues (OR = 13.04, 95%CI = 4.07-41.71, P < .001).
Conclusion: This pooled analysis indicated that FoxM1 expression related to lymph node metastasis, distant metastasis, TNM stage and poor prognosis of the CRC patients.
Conflict of interest statement
There is no conflict of interest in this study.
Figures






Similar articles
-
Evaluation of Forkhead BOX M1 (FOXM1) gene expression in colorectal cancer.Clin Exp Med. 2023 Oct;23(6):2385-2405. doi: 10.1007/s10238-022-00929-7. Epub 2022 Nov 1. Clin Exp Med. 2023. PMID: 36318377
-
Clinicopathological and prognostic significance of FoxM1 in gastric cancer: A meta-analysis.Int J Surg. 2017 Dec;48:38-44. doi: 10.1016/j.ijsu.2017.09.076. Epub 2017 Oct 7. Int J Surg. 2017. PMID: 29017864 Review.
-
FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer.Acta Histochem. 2012 Dec;114(8):755-62. doi: 10.1016/j.acthis.2012.01.002. Epub 2012 Feb 11. Acta Histochem. 2012. PMID: 22326401
-
Clinical value and potential association of Rab1A and FoxM1 aberrant expression in colorectal cancer.Sci Rep. 2020 Nov 19;10(1):20160. doi: 10.1038/s41598-020-77182-z. Sci Rep. 2020. PMID: 33214609 Free PMC article.
-
Prognostic and clinicopathological value of MUC1 expression in colorectal cancer: A meta-analysis.Medicine (Baltimore). 2019 Mar;98(9):e14659. doi: 10.1097/MD.0000000000014659. Medicine (Baltimore). 2019. PMID: 30817589 Free PMC article.
Cited by
-
Identification of key regulators associated with colon cancer prognosis and pathogenesis.J Cell Commun Signal. 2022 Mar;16(1):115-127. doi: 10.1007/s12079-021-00612-8. Epub 2021 Mar 26. J Cell Commun Signal. 2022. PMID: 33770351 Free PMC article.
-
Evaluation of Forkhead BOX M1 (FOXM1) gene expression in colorectal cancer.Clin Exp Med. 2023 Oct;23(6):2385-2405. doi: 10.1007/s10238-022-00929-7. Epub 2022 Nov 1. Clin Exp Med. 2023. PMID: 36318377
-
MiR-216b suppresses cell proliferation, migration, invasion, and epithelial-mesenchymal transition by regulating FOXM1 expression in human non-small cell lung cancer.Onco Targets Ther. 2019 Apr 18;12:2999-3009. doi: 10.2147/OTT.S202523. eCollection 2019. Onco Targets Ther. 2019. PMID: 31114243 Free PMC article.
-
Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies.Cell Death Discov. 2024 May 2;10(1):211. doi: 10.1038/s41420-024-01929-0. Cell Death Discov. 2024. PMID: 38697979 Free PMC article.
-
Long noncoding RNA HOXC-AS3 facilitates the progression of invasive mucinous adenocarcinomas of the lung via modulating FUS/FOXM1.In Vitro Cell Dev Biol Anim. 2020 Jan;56(1):15-23. doi: 10.1007/s11626-019-00414-8. Epub 2020 Jan 10. In Vitro Cell Dev Biol Anim. 2020. PMID: 31925650
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7–30. - PubMed
-
- Shimada H, Tanaka K, Endou I, et al. Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg 2009;394:973–83. - PubMed
-
- Ning Z, Wang A, Liang J, et al. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via beta-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma. Int J Oncol 2014;45:1594–608. - PubMed
-
- Bella L, Zona S, Nestal de Moraes G, et al. FOXM1: a key oncofoetal transcription factor in health and disease. Semin Cancer Biol 2014;29:32–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous